Revusiran

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameRevusiran
Drug Alias NameSiTTRscALN-TTRscSAR438714SAR-438714
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionTransthyretin inhibitorsRNA interference
TargetsTransthyretin
Therapy Area/IndicationsTransthyretin amyloidosisAmyloidosisAmyloidosis, Familial +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsTransthyretin amyloidosisAmyloidosisAmyloidosis, Familial +[6] 

Other Information

ATC CodeN/A
Related LinksN/A